Veri MedTech is seeking a debut on the Nasdaq exchange and is currently undergoing review by the SEC.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Veri MedTech is seeking a debut on the Nasdaq exchange and is currently undergoing review by the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Silicon Laboratories stock traded on Nasdaq and required SEC filings on September 8, 2026.
- BioLineRx Ltd. is utilizing the Nasdaq stock exchange for a registered direct offering, filing with the SEC.
- Precigen, Inc. listed on the Nasdaq stock exchange and filed disclosures with the SEC on August 25, 2026.
- Jones Ventures INTL Acquisition1 Corp. filed its registration statement with the SEC and announced its IPO listing on Nasdaq Global Market.
- Argenex SE and Capricor Therapeutics were listed on the Nasdaq stock exchange and are competing in the biotech sector.